Novartis upholds MS drug patent at Fed Circ

04-01-2022

Muireann Bolger

Novartis upholds MS drug patent at Fed Circ

Taljat David / Shutterstock.com

Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya (fingolimod hydrochloride) was valid.


Novartis, Fed Circ, patent, HEC Pharm, Gilenya

LSIPR